Kalda A, Yu L, Oztas E, Chen JF (October 2006). „Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease”. Journal of the Neurological Sciences248 (1-2): 9–15. DOI:10.1016/j.jns.2006.05.003. PMID16806272.
Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF (September 2007). „Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function”. Physiology & Behavior92 (1-2): 210–7. DOI:10.1016/j.physbeh.2007.05.034. PMID17572452.
Cohen MV, Downey JM (May 2008). „Adenosine: trigger and mediator of cardioprotection”. Basic Research in Cardiology103 (3): 203–15. DOI:10.1007/s00395-007-0687-7. PMID17999026.
Ferré S (May 2008). „An update on the mechanisms of the psychostimulant effects of caffeine”. Journal of Neurochemistry105 (4): 1067–79. DOI:10.1111/j.1471-4159.2007.05196.x. PMID18088379.
Osadchii OE (June 2007). „Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease”. Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy21 (3): 171–94. DOI:10.1007/s10557-007-6014-6. PMID17373584.
Baraldi PG, Tabrizi MA, Gessi S, Borea PA (January 2008). „Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility”. Chemical Reviews108 (1): 238–63. DOI:10.1021/cr0682195. PMID18181659.
Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008). „A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists”. Current Pharmaceutical Design14 (15): 1525–52. DOI:10.2174/138161208784480081. PMID18537675.
Kalda A, Yu L, Oztas E, Chen JF (October 2006). „Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease”. Journal of the Neurological Sciences248 (1-2): 9–15. DOI:10.1016/j.jns.2006.05.003. PMID16806272.
Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF (September 2007). „Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function”. Physiology & Behavior92 (1-2): 210–7. DOI:10.1016/j.physbeh.2007.05.034. PMID17572452.
Cohen MV, Downey JM (May 2008). „Adenosine: trigger and mediator of cardioprotection”. Basic Research in Cardiology103 (3): 203–15. DOI:10.1007/s00395-007-0687-7. PMID17999026.
Ferré S (May 2008). „An update on the mechanisms of the psychostimulant effects of caffeine”. Journal of Neurochemistry105 (4): 1067–79. DOI:10.1111/j.1471-4159.2007.05196.x. PMID18088379.
Osadchii OE (June 2007). „Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease”. Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy21 (3): 171–94. DOI:10.1007/s10557-007-6014-6. PMID17373584.
Baraldi PG, Tabrizi MA, Gessi S, Borea PA (January 2008). „Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility”. Chemical Reviews108 (1): 238–63. DOI:10.1021/cr0682195. PMID18181659.
Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008). „A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists”. Current Pharmaceutical Design14 (15): 1525–52. DOI:10.2174/138161208784480081. PMID18537675.